Pacira BioSciences Announces Conclusion of EXPAREL Agreement with DePuy Synthes
(WorldNews Environment)

Pacira BioSciences Announces Conclusion of EXPAREL Agreement with DePuy Synthes July 2, 2020 -- Orthopedic co-promotion agreement to conclude in January 2021 ---- Significantly improves Pacira economics related to EXPAREL -- PARSIPPANY, N.J., July 02, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options, today announced that the company has notified DePuy Synthes Sales Inc. that the agreement between the two companies to jointly market and promote the use of EXPAREL® (bupivacaine injectable suspension) for orthopedic procedures in the United States will terminate on January 2, 2021. Under this collaboration,...